MX2023008589A - Compuestos moduladores de gcn2 y usos de los mismos. - Google Patents
Compuestos moduladores de gcn2 y usos de los mismos.Info
- Publication number
- MX2023008589A MX2023008589A MX2023008589A MX2023008589A MX2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A MX 2023008589 A MX2023008589 A MX 2023008589A
- Authority
- MX
- Mexico
- Prior art keywords
- gcn2
- modulating compounds
- modulating
- compounds
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008589A true MX2023008589A (es) | 2023-08-09 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008589A MX2023008589A (es) | 2021-01-22 | 2022-01-21 | Compuestos moduladores de gcn2 y usos de los mismos. |
Country Status (14)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| KR20250017238A (ko) * | 2022-05-25 | 2025-02-04 | 히버셀, 인크. | 암을 치료하기 위한 gcn2 조정제 |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| EP4652170A1 (en) * | 2023-01-20 | 2025-11-26 | Hibercell, Inc. | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3- sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[l,5- ajpyrazine-l-carboxamide and methods for using the same |
| IL328829A (en) * | 2023-12-08 | 2026-08-01 | Hibercell Inc | Methods for treating acute myeloid leukemia using combinations of GCN2 modulators, ventocalx and azaraglitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005034869A2 (en) * | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| PL3498693T3 (pl) * | 2016-08-10 | 2025-03-24 | Takeda Pharmaceutical Company Limited | Związek heterocykliczny |
| CA3089762A1 (en) * | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| EP4107146A1 (en) * | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
-
2022
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022159746A1 (en) | 2022-07-28 |
| AU2022210760A1 (en) | 2023-09-07 |
| US20240083897A1 (en) | 2024-03-14 |
| PE20240691A1 (es) | 2024-04-10 |
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| BR112023014723A2 (pt) | 2023-10-03 |
| CN117203206A (zh) | 2023-12-08 |
| KR20240021143A (ko) | 2024-02-16 |
| CO2023010940A2 (es) | 2023-12-11 |
| JP2024504364A (ja) | 2024-01-31 |
| CA3209124A1 (en) | 2022-07-28 |
| IL304611A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230408A (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| WO2025049274A3 (en) | Tetracyclic derivatives, compositions and methods thereof | |
| WO2020163823A3 (en) | Therapeutic agents and methods of treatment | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| AU2019362061A8 (en) | Androgen receptor modulators and methods for their use | |
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| PH12021550786A1 (en) | Prodrug modulators of the integrated stress pathway | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| MX2023005928A (es) | Moduladores de malt-1. | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| CR20230057A (es) | Compuestos tríciclicos de urea como inhibidores de jak2 v617f | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
| MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| MY201080A (en) | Nlrp3 modulators | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| MX2025007384A (es) | Inhibidores de malt1 | |
| WO2019143883A3 (en) | Compositions and methods for the treatment of cancer | |
| CA3196916A1 (en) | Modulators of the integrated stress pathway | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. |